Molecular Pharmaceutics Laboratory, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1, Noji-higashi, Kusatsu, Shiga 525-8577, Japan.
Mol Pharm. 2024 Jun 3;21(6):2854-2864. doi: 10.1021/acs.molpharmaceut.4c00028. Epub 2024 May 8.
The purpose of the present study was to clarify whether the precipitation profile of a drug in bicarbonate buffer (BCB) may differ from that in phosphate buffer (PPB) by a well-controlled comparative study. The precipitation profiles of structurally diverse poorly soluble drugs in BCB and PPB were evaluated by a pH-shift precipitation test or a solvent-shift precipitation test (seven weak acid drugs (p: 4.2 to 7.5), six weak base drugs (p: 4.8 to 8.4), one unionizable drug, and one zwitterionic drug). To focus on crystal precipitation processes, each ionizable drug was first completely dissolved in an HCl (pH 3.0) or NaOH (pH 11.0) aqueous solution (450 mL, 50 rpm, 37 °C). A 10-fold concentrated buffer solution (50 mL) was then added to shift the pH value to 6.5 to initiate precipitation (final volume: 500 mL, buffer capacity (β): 4.4 mM/ΔpH (BCB: 10 mM or PPB: 8 mM), ionic strength (): 0.14 M (adjusted by NaCl)). The pH, β and values were set to be relevant to the physiology of the small intestine. For an unionizable drug, a solvent-shift method was used (1/100 dilution). To maintain the pH value of BCB, a floating lid was used to avoid the loss of CO. The floating lid was applied also to PPB to precisely align the experimental conditions between BCB and PPB. The solid form of the precipitants was identified by powder X-ray diffraction and differential scanning microscopy. The precipitation of weak acids (p ≤ 5.1) and weak bases (p ≥ 7.3) was found to be slower in BCB than in PPB. In contrast, the precipitation profiles in BCB and PPB were similar for less ionizable or nonionizable drugs at pH 6.5. The final pH values of the bulk phase were pH 6.5 ± 0.1 after the precipitation tests in all cases. All precipitates were in their respective free forms. The precipitation of ionizable weak acids and bases was slower in BCB than in PPB. The surface pH of precipitating particles may have differed between BCB and PPB due to the slow hydration process of CO specific to BCB. Since BCB is a physiological buffer in the small intestine, it should be considered as an option for precipitation studies of ionizable weak acids and bases.
本研究的目的是通过一项精心控制的对比研究来阐明药物在碳酸氢盐缓冲液(BCB)中的沉淀形态是否与在磷酸盐缓冲液(PPB)中的沉淀形态不同。通过 pH 迁移沉淀试验或溶剂迁移沉淀试验(七种弱酸药物(pKa:4.2 至 7.5)、六种弱碱性药物(pKa:4.8 至 8.4)、一种不可离解药物和一种两性离子药物)评估了结构多样的难溶性药物在 BCB 和 PPB 中的沉淀形态。为了专注于晶体沉淀过程,首先将每种可离子化的药物完全溶解在 HCl(pH 3.0)或 NaOH(pH 11.0)水溶液(450 mL,50 rpm,37°C)中。然后加入 10 倍浓缩缓冲液溶液(50 mL)将 pH 值调至 6.5 以引发沉淀(最终体积:500 mL,缓冲能力(β):4.4 mM/ΔpH(BCB:10 mM 或 PPB:8 mM),离子强度():0.14 M(用 NaCl 调节))。pH、β和 值被设置为与小肠的生理学相关。对于不可离解的药物,使用溶剂迁移法(1/100 稀释)。为了保持 BCB 的 pH 值,使用浮动盖避免 CO 的损失。浮动盖也用于 PPB,以精确对齐 BCB 和 PPB 之间的实验条件。通过粉末 X 射线衍射和差示扫描显微镜鉴定沉淀物的固体形式。在 BCB 中,弱酸(p ≤ 5.1)和弱碱(p ≥ 7.3)的沉淀速度比在 PPB 中慢。相比之下,在 pH 6.5 下,对于较少可离解或不可离解的药物,BCB 和 PPB 中的沉淀形态相似。所有沉淀试验后,所有情况下的体相最终 pH 值均为 6.5 ± 0.1。所有沉淀物均以各自的游离形式存在。在 BCB 中,可离解的弱酸和弱碱的沉淀速度比在 PPB 中慢。由于 BCB 是小肠中的生理缓冲液,因此在研究可离解弱酸和弱碱的沉淀时应将其作为一种选择。